|
Arginase actions and their responses in the vasculature |
Reference | Type of study | Study design | Type of arginase involved | Actions/results | Vascular damage |
|
[12] | Preclinical | In vivo study with postmortem analysis in wild type C57Bl/6 and arginase II knockout male mouse (assessment of cigarette smoke effects) | Arg II | | |
[15] | Clinical | In vivo study performed in patients with coronary artery disease and type 2 diabetes mellitus | Arg I and Arg II |
[21] | Preclinical | In vivo study with male ApoE−/− and C57Bl/6 mouse and postmortem analysis | Arg II |
[70] | Preclinical | In vivo model of transgenic C57Bl/6 mouse overexpressing human arginase II, with postmortem analysis | Arg II |
[82] | Preclinical | In vitro study in cell culture of isolated porcine carotid endothelium | Arg II |
[96] | Clinical | Clinical study with blood samples of patients with type 2 diabetes mellitus | Arg I and Arg II |
[97] | Preclinical | In vitro study using isolated mouse aortic endothelium and HUVECs cultures | Arg II |
[6] | Clinical | Human popliteal and tibial vessels from amputation specimens (ex vivo model) | Arg II | Reduction of •NO bioavailability | Endothelial dysfunction |
[48] | Preclinical | In vivo and in vitro study using culture of human aortic endothelial cells (HAECs) and C57Bl/6 mouse aortic rings | Arg II |
[50] | Preclinical | In vitro study performed on rat aorta endothelial cells (AECs) | Arg I and Arg II |
[80] | Preclinical | In vitro study performed on HUVEC and Wistar rat aortic rings | Arg II |
[81] | Preclinical | In vitro study performed on culture of human aortic endothelial cells and Wistar rat aortic rings | Arg I and Arg II |
[95] | Preclinical | In vitro study with treatment in HUVECs and mouse aortic rings | Arg I and Arg II |
[98] | Preclinical | Study performed on HUVECs culture in vitro and isolated C57Bl/6 mouse aorta | Arg I and Arg II |
[69] | Preclinical | In vitro study using HUVECs culture and in vivo treatment in C57Bl/6 mice | Arg I and Arg II |
[12] | Preclinical | In vivo study with postmortem analysis in C57Bl/6 and arginase II knockout male mice (assessment of cigarette smoke effects) | Arg II | Uncoupling of eNOS | Increased ROS production |
[21] | Preclinical | In vivo study with male ApoE−/− and C57Bl6 mice and postmortem analysis | Arg II |
[48] | Preclinical | In vivo and in vitro study using culture of human aortic endothelial cells (HAECs) and C57Bl/6 mouse aortic rings | Arg II |
[69] | Preclinical | In vitro study using HUVECs culture and in vivo treatment in C57BL/6 mice | Arg I and Arg II |
[80] | Preclinical | In vitro study performed on HUVEC and Wistar rat aortic rings | Arg II |
[97] | Preclinical | In vitro study using isolated mouse aortic endothelium and HUVECs cultures | Arg II |
[95] | Preclinical | Study performed on HUVECs culture in vitro and isolated C57BL/6 mouse aorta | Arg I and Arg II |
[98] | Preclinical | Study performed on HUVECs culture in vitro and isolated C57BL/6 mouse aorta | Arg I and Arg II | | |
[69] | Preclinical | In vitro study using HUVECs culture and in vivo treatment in C57Bl/6 mouse | Arg I and Arg II |
[82] | Preclinical | In vitro study in cell culture of isolated porcine carotid endothelium | Arg II |
[83] | Preclinical | In vitro (VSMCs from human umbilical vein) and in vivo (ApoE−/− and C57Bl/6 mouse) study | Arg II |
|